PDF
ePub
Citation
Print
Abstract
Majority of cancer patients used CAM modalities during and even after cancer treatment. Main reasons for CAM use are to improve immunity, with expectation of fewer recurrences, and to have better quality of life. Still many patients did not reveal precise detailed information of CAM use to their physicians. Due to possible interaction between herbs and cancer drugs, it is essential for physicians to know whether their patients use CAM modalities or not and to have interest in existing evidence. This article will provide the lists of evidence and references on supplements and life styles including diet and exercise. Mind body medicine is not commonly used in Korea but there is increasing evidence on meditation and usefulness with relaxation even in supportive care.
References
1. Ock SM, Choi JY, Cha YS, Lee J, Chun MS, Huh CH, Lee SY, Lee SJ. The use of complementary and alternative medicine in a general population in South Korea: results from a national survey in 2006 . J Korean Med Sci. 2009. 24:1–6.
2. Kim CB, Yhe BL, Park JH. Understanding cancer patients who seek Complementary and Alternative therapies and Searching developments of its management in South Korea. National R&D Program for Cancer Control(0720600). 2008.
3. Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA, Adjei AA. Nutritional supplements use by patients enrolled onto phase I clinical trials. J Clin Oncol. 2004. 22:4810–4815.
4. Carpenter CL, Ganz PA, Bernstein L. Complementary and alternative therapies among very long-term breast cancer survivors. Breast Cancer Res Treat. 2009. 116:387–396.
5. Tough SC, Johnston DW, Verhoef MJ, Arthur K, Bryant H. Complementary and alternative medicine use among colorectal cancer patients in Alberta, Canada. Altern Ther Health Med. 2002. 8:54–56. 58–60. 62–64.
6. Mao JJ, Palmer SC, Straton JB, Cronholm PF, Keddem S, Knott K, Bowman MA, Barg FK. Cancer survivors with unmet needs were more likely to use complementary and alternative medicine. J Cancer Surviv. 2008. 2:116–124.
7. Frenkel M, Ben-Arye E, Baldwin CD, Sierpina V. Approach to communicating with patients about the use of nutritional supplements in cancer care. South Med J. 2005. 98:289–294.
8. Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM, Platin N, Kearney N, Patiraki E. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005. 16:655–663.
9. Lafferty WE, Tyree PT, Devlin SM, Andersen MR, Diehr PK. Complementary and alternative medicine provider use and expenditures by cancer treatment phase. Am J Manag Care. 2008. 14:326–334.
10. Alexander DD, Cushing CA, Lowe KA, Sceurman B, Roberts MA. Meta-analysis of animal fat or animal protein intake and colorectal cancer. Am J Clin Nutr. 2009. 89:1402–1409.
11. McAfee Aj, McSorley EM, Cuskelly GJ, Moss BW, Wallace JM, Fearon B. Red meat consumption: an overview of the risks and benefits. Meat Sci. 2009. 84:1–13.
12. Cross AJ, Ferrucci LM, Risch A, Graubard BI, Ward MH, Park Y, Hollenbeck AR, Schatzkin A, Sinha R. A Large Prospective Study of Meat Consumption and Colorectal Cancer Risk: An Investigation of Potential Mechanisms Underlying this Association. Cancer Res. 2010. 70:2406–2414.
13. Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007. 298:754–764.
14. Wei EK, Colditz GA, Giovannucci EL, Fuchs CS, Rosner BA. Cumulative risk of colon cancer up to age 70 years by risk factor status using data from the Nurses' Health Study. Am J Epidemiol. 2009. 170:863–872.
15. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a
prospectively studied cohort of U.S. adults. N Engl J Med. 2003. 348:1625–1638.
16. Barrera S, Demark-Wahnefried W. Nutrition during and after cancer therapy. Oncology (Williston Park). 2009. 23:2 Suppl Nurse Ed. 15–21.
17. Hardy ML. Dietary supplement use in cancer care: help or harm. Hematol Oncol Clin North Am. 2008. 22:581–617.
18. Cassileth BR, Lusk EJ, Guerry D, Blake AD, Walsh WP, Kascius L, Schultz DJ. Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med. 1991. 324:1180–1185.
19. White J. PC-SPES--a lesson for future dietary supplement research. J Natl Cancer Inst. 2002. 94:1261–1263.
20. Seeff LB. Herbal hepatotoxicity. Clin Liver Dis. 2007. 11:577–596.
21. Dennis T, Fanous M, Mousa S. Natural products for chemopreventive and adjunctive therapy in oncologic disease. Nutr Cancer. 2009. 61:587–597.
22. Delia P, Sansotta G, Donato V, Frosina P, Messina G, De Renzis C, Famularo G. Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol. 2007. 13:912–915.
23. Sugawara G, Nagino M, Nishio H, Ebata T, Takagi K, Asahara T, Nomoto K, Nimura Y. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann Surg. 2006. 244:706–714.
24. Kinross J, Warren O, Silk D, Darzi A. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized control trial. Ann Surg. 2007. 245:1000.
25. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG. Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomized, double-blind, placebo-controlled trial. Lancet. 2008. 371:651–659.
26. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009. 301:39–51.
27. Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol. 2009. 27:3577–3583.
28. Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK, Glisson BS, Lee JS. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol. 2001. 19:1830–1838.
29. Laurie SA, Miller VA, Grant SC, Kris MG, Ng KK. Phase I study of green tea extract in patients with advanced lung cancer. Cancer Chemother Pharmacol. 2005. 55:33–38.
30. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009. 2:931–941.
31. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, Mouret-Reynier MA, Durando X, Barthomeuf C, Chollet P. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther. 2010. 9:8–14.
32. Ju YH, Allred CD, Allred KF, Karko KL, Doerge DR, Helferich WG. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogendependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr. 2001. 131:2957–2962.
33. Messina M, Wu AH. Perspectives on the soy-breast cancer relation. Am J Clin Nutr. 2009. 89:1673S–1679S.
34. Lethaby AE, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2007. (4):CD001395.
35. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol. 2004. 22:2489–2503.
36. Seely D, Oneschuk D. Interactions of natural health products with biomedical cancer treatments. Curr Oncol. 2008. 15:Suppl 2. s109.es81–s110.es86.
37. Shord SS, Shah K, Lukose A. Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals. Integr Cancer Ther. 2009. 8:208–227.
38. van Erp NP, Baker SD, Zhao M, et al. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res. 2005. 11:7800–7806.
39. Cox MC, Low J, Lee J, et al. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res. 2006. 12:4636–4640.
40. van der Bol JM, Mathijssen RH, Loos WJ, Friberg LE, van Schaik RH, de Jonge MJ, Planting AS, Verweij J, Sparreboom A, de Jong FA. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol. 2007. 25:2719–2726.
41. Ladas EJ, Jacobson JS, Kennedy DD, Teel K, Fleischauer A, Kelly KM. Antioxidants and cancer therapy: a systematic review. J Clin Oncol. 2004. 22:517–528.
42. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1978. 75:4538–4542.
43. Cameron E, Campbell A. Innovation vs. quality control: an 'unpublishable' clinical trial of supplemental ascorbate in incurable cancer. Med Hypotheses. 1991. 36:185–189.
44. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized doubleblind comparison. N Engl J Med. 1985. 312:137–141.
45. Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA, O'Connor OA. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res. 2008. 68:8031–8038.
46. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. Cancer Treat Rev. 2007. 33:407–418.
47. Simone CB 2nd, Simone NL, Simone V, Simone CB. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. Altern Ther Health Med. 2007. 13:22–28.
48. Bairati I, Meyer F, Gélinas M, Fortin A, Nabid A, Brochet F, Mercier JP, Têtu B, Harel F, Abdous B, Vigneault E, Vass S, Del Vecchio P, Roy J. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol. 2005. 23:5805–5813.
49. Bairati I, Meyer F, Jobin E, Gélinas M, Fortin A, Nabid A, Brochet F, Têtu B. Antioxidant ê vitamins supplementation and mortality: a randomized trial in head and neck cancer patients. Int J Cancer. 2006. 119:2221–2224.
50. Meyer F, Bairati I, Fortin A, Gélinas M, Nabid A, Brochet F, Têtu B. Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: a randomized trial among head and neck cancer patients. Int J Cancer. 2008. 122:1679–1683.
51. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst. 2008. 100:773–783.
52. Speck RM, Courneya KS, Mâsse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv. 2010. 01. 6. [Epub ahead of print].
53. Meyerhardt JA, Giovannucci EL, Holmes MD, Chan AT, Chan JA, Colditz GA, Fuchs CS. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol. 2006. 24:3527–3534.
54. Meyerhardt JA, Giovannucci EL, Ogino S, Kirkner GJ, Chan AT, Willett W, Fuchs CS. Physical activity and male colorectal cancer survival. Arch Intern Med. 2009. 169:2102–2108.
55. Adamsen L, Quist M, Andersen C, Møller T, Herrstedt J, Kronborg D, Baadsgaard MT, Vistisen K, Midtgaard J, Christiansen B, Stage M, Kronborg MT, Rørth M. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ. 2009. 339:b3410.
56. Harris SR. Physical activity and breast cancer mortality. Eur J Oncol Nurs. 2009. 13:233–234.
57. Mustian KM, Peppone L, Darling TV, Palesh O, Heckler CE, Morrow GR. A 4-week home-based aerobic and resistance exercise program during radiation therapy: a pilot randomized clinical trial. J Support Oncol. 2009. 7:158–167.
58. Sagen A, Kåresen R, Risberg MA. Physical activity for the affected limb and arm lymphedema after breast cancer surgery. A prospective, randomized controlled trial with two years follow-up. Acta Oncol. 2009. 48:1102–1110.
59. Schmitz KH, Ahmed RL, Troxel A, Cheville A, Smith R, Lewis-Grant L, Bryan CJ, Williams-Smith CT, Greene QP. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med. 2009. 361:664–673.
60. Moan J, Porojnicu A, Lagunova Z, Berg JP, Dahlback A. Colon cancer: prognosis for different latitudes, age groups and seasons in Norway. J Photochem Photobiol B. 2007. 89:148–155.
61. Moan J, Dahlback A, Porojnicu AC. At what time should one go out in the sun? Adv Exp Med Biol. 2008. 624:86–88.
62. Moan J, Dahlback A, Lagunova Z, Cicarma E, Porojnicu AC. Solar radiation, vitamin D and cancer incidence and mortality in Norway. Anticancer Res. 2009. 29:3501–3509.
63. Ng K, Wolpin BM, Meyerhardt JA, Wu K, Chan AT, Hollis BW, Giovannucci EL, Stampfer MJ, Willett WC, Fuchs CS. Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer. Br J Cancer. 2009. 101:916–923.
64. Cheung YL, Molassiotis A, Chang AM. The effect of progressive muscle relaxation training on anxiety and quality of life after stoma surgery in colorectal cancer patients. Psychooncology. 2003. 12:254–266.
65. Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology. 2004. 29:448–474.
66. Carlson LE, Speca M, Faris P, Patel KD. One year prepost intervention follow-up of psychological, immune, endocrine and blood pressure outcomes of mindfulness-based stress reduction (MBSR) in breast and prostate cancer outpatients. Brain Behav Immun. 2007. 21:1038–1049.
67. Carlson LE, Bultz BD. Mind-body interventions in oncology. Curr Treat Options Oncol. 2008. 9:127–134.
68. Kwekkeboom KL, Cherwin CH, Lee JW, Wanta B. Mind-body treatments for the pain-fatigue-sleep disturbance symptom cluster in persons with cancer. J Pain Symptom Manage. 2010. 39:126–138.
69. Ernst E, Pittler MH, Wider B, Boddy K. Complementary/alternative medicine for supportive cancer care: development of the evidence-base. Support Care Cancer. 2007. 15:565–568.
70. Tasaki K, Maskarinec G, Shumay DM, Tatsumura Y, Kakai H. Communication between physicians and cancer patients about complementary and alternative medicine: exploring patients' perspectives. Psychooncology. 2002. 11:212–220.
71. Kim DY, Lee HR, Nam EM. Assessing cancer treatment related information online: unintended retrieval of complementary and alternative medicine web sites. Eur J Cancer Care (Engl). 2009. 18:64–68.
72. Brauer JA, El Sehamy A, Metz JM, Mao JJ. Complementary and alternative medicine and supportive care at leading cancer centers: a systematic analysis of websites. J Altern Complement Med. 2010. 16:183–186.
XML Download